Drug
HMPL-013 clinical trials
Also written Fruquintinib, HMPL-013 and Fruzaqla.
Keep track of what changes. Save the HMPL-013 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
109 studies that test it; most in 2022 (19)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 9 |
| 2022 | 19 |
| 2023 | 17 |
| 2024 | 12 |
| 2025 | 19 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 82
Hutchison Medipharma Limited (15) · Fudan University (14) · Hutchmed (7) · Sun Yat-sen University (7) · Federation Francophone de Cancerologie Digestive (3) · RenJi Hospital (2) · Wuhan Union Hospital, China (2) · Harbin Medical University (2)
Often tested with
Tested in the same studies.
Tislelizumab (13) · Sintilimab (13) · Capecitabine (7) · Paclitaxel (4) · FOLFIRI-Ziv-aflibercept Regimen (4) · FOLFIRI Regimen (4) · Serplulimab (3) · Tucidinostat (3)
Studies
Open first, then newest update. How each study uses HMPL-013 is read from its arms, and is right about nine times in ten.
Testing it · 109
- SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal CancerRecruitingPhase 2Ruijin HospitalNCT07888309Written as Fruquintinib
- A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerNot yet recruitingPhase 2Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterNCT07819019Written as Fruquintinib
- Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06484153Written as Fruquintinib
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNot applicableHarbin Medical UniversityNCT07552402Written as Oral Paclitaxel Solution Plus Fruquintinib
- Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRCRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07724223Written as Fruquintinib plus Cetuximab-beta
- Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07689292Written as Sacituzumab Tirumotecan + Fruquintinib
- A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal CancerRecruitingPhase 4TakedaNCT06562543Written as Fruquintinib
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingPhase 2SCRI Development Innovations, LLCNCT07011576Written as fruquintinib
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07622550Written as Serplulimab+Fruquintinib+XELOX
- Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal CancerRecruitingNot applicableFederation Francophone de Cancerologie DigestiveNCT07124858Written as Fruquintinib
- Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal CancerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07042685Written as Fruquintinib Combined With Chemotherapy
- Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)Not yet recruitingPhase 2Korea University Anam HospitalNCT07510932Written as Fruquintinib
- FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal CancerNot yet recruitingPhase 4Ye XuNCT07446465Written as Fruquintinib
- Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric CancerRecruitingPhase 2Dai, GuanghaiNCT07392346Written as Fruquintinib
- Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric AdenocarcinomaRecruitingPhase 3Federation Francophone de Cancerologie DigestiveNCT07270991Written as fruquintinib
- Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)Not yet recruitingPhase 3Fudan UniversityNCT07362836Written as fruquintinib+chemotherapy
- A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyRecruitingPhase 2Fudan UniversityNCT05954429Written as Fruquintinib
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06856837Written as Fruquintinib
- Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07261709Written as Trifluridine/tipiracil plus fruquintinib
- A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above TreatmentNot yet recruitingPhase 2Harbin Medical UniversityNCT07229872Written as Fruquintinib
See all 109 studies that test HMPL-013 →
Given in every arm · 14 — HMPL-013 is usual care beside what is tested
- A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal CarcinomaRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07791758Written as Fruquintinib Capsules
- A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal CancerNot yet recruitingPhase 1/2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07621159Written as Fruquintinib
- A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerNot yet recruitingPhase 1/2National Cancer Center Hospital EastNCT07591597Written as Fruquintinib
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal CancerNot yet recruitingPhase 2Huazhong University of Science and TechnologyNCT07502014Written as Fruquintinib
- A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.RecruitingPhase 1/2AskGene Pharma, Inc.NCT05867420Written as Fruquintinib
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Adagene IncNCT05405595Written as Standard of care (Fruquintinib)
- Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal CancerRecruitingPhase 2/3Sun Yat-sen UniversityNCT06441565Written as Fruquintinib
- Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNot applicableLiu HuangNCT06551207Written as Fruquintinib
- Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal CancerRecruitingEarly Phase 1Wuhan Union Hospital, ChinaNCT06347198Written as Fruquintinib
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid TumorsActive, not recruitingPhase 1Sapience TherapeuticsNCT05848739Written as Fruquintinib
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as Fruquintinib
- Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingPhase 1/2Immunitas TherapeuticsNCT05565417Written as Fruquintinib
- A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic TherapyStatus unknownPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05511051Written as Fruquintinib
- Fruquintinib CYP3A Inhibitor and Inducer StudyCompletedPhase 1Hutchison Medipharma LimitedNCT04557397Written as Fruquintinib
As the comparator · 4 — what is tested is compared with HMPL-013
- A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerRecruitingPhase 2Criterium, Inc.NCT06992258Written as Fruquintinib
- A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07730489Written as Fruquintinib
- A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.RecruitingPhase 2Kahr Bio Australia Pty LtdNCT07235293Written as Fruquintinib
- A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingPhase 3Chipscreen Biosciences, Ltd.NCT06497985Written as Fruquintinib
Codes
What other systems call HMPL-013 · ClinicalTrials.gg INT000075
- MeSH (NLM) C000591844HMPL-013Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 49DXG3M5ZWFRUQUINTINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000591844 | HMPL-013 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 49DXG3M5ZW | FRUQUINTINIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.